REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2012

Feb 16, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2012-02-15

Reporting Person: YANCOPOULOS GEORGE (Director, EVP CSO President Regeneron Re)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-02-15	Common Stock	M	129902	$8.5	Acquired	962943	Direct
2012-02-15	Common Stock	F	10103	$109.29	Disposed	952840	Direct
2012-02-15	Common Stock	F	55191	$109.29	Disposed	897649	Direct
2012-02-15	Common Stock	M	3430	$8.5	Acquired	901079	Direct
2012-02-15	Common Stock	F	266	$109.29	Disposed	900813	Direct
2012-02-15	Common Stock	F	1457	$109.29	Disposed	899356	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-02-15	Non-Qualified Stock Option (right to buy)	$8.5	M	129902	Disposed	2012-12-20	Common Stock (129902)	Direct
2012-02-15	Non-Qualified Stock Option (right to buy)	$8.5	M	3430	Disposed	2012-12-20	Common Stock (3430)	Direct
2012-02-15	Non-Qualified Stock Option (right to buy)	$109.29	A	10103	Acquired	2012-12-20	Common Stock (10103)	Direct
2012-02-15	Non-Qualified Stock Option (right to buy)	$109.29	A	266	Acquired	2012-12-20	Common Stock (266)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	5534	Indirect

Footnotes

F1: The option became exercisable with respect to all shares underlying the option upon the satisfaction by the company of certain performance criteria on February 10, 2012.

F2: Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.